PMID- 38074645
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231211
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Anlotinib combined with transarterial chemoembolization for unresectable 
      hepatocellular carcinoma associated with hepatitis B virus: a retrospective 
      controlled study.
PG  - 1235786
LID - 10.3389/fonc.2023.1235786 [doi]
LID - 1235786
AB  - PURPOSE: To investigate the efficacy and safety of combined treatment of 
      anlotinib and transarterial chemoembolization (TACE) in patients with 
      unresectable hepatocellular carcinoma (uHCC) associated with hepatitis B virus 
      (HBV) infection. METHODS: We retrospectively collected the data of 96 uHCC 
      patients associated with HBV infection who received either TACE only (TO group; n 
      = 64) or anlotinib combined with TACE (TA group; n = 32) from January 2017 to 
      January 2021. The primary endpoint was overall survival (OS). The secondary 
      outcomes included progression-free survival (PFS), tumor response according to 
      modified Response Evaluation Criteria in Solid Tumors (mRECIST) and RECIST 1.1, 
      and adverse events (AEs). RESULTS: The median OS and median PFS were 
      significantly longer in the TA group compared to the TO group (17.6 months vs. 
      9.4 months, p = 0.018; 6.7 months vs. 3.8 months, p = 0.003, respectively). In 
      addition, the overall objective response rate (ORR) and disease control rate 
      (DCR) numerically increased in the TA group (mRECIST, ORR 65.6% vs. 46.9%, p = 
      0.064, DCR 90.6% vs. 85.9%, p = 0.382; RECIST 1.1, ORR 46.9% vs. 15.6%, p = 
      0.001, DCR 90.6% vs. 85.9%, p = 0.382, respectively). It was worth noting that no 
      treatment-related mortality occurred during the study. The most common AEs 
      included elevated transaminases (56.3%), decreased appetite (46.9%), and 
      abdominal pain (37.5%) in the TA group. Although the incidence rate of grade 3/4 
      AEs was higher in the TA group, all of them were controllable. CONCLUSIONS: The 
      combination of anlotinib and TACE has shown promising results in improving 
      outcomes for patients with HBV-related uHCC, as compared to TACE monotherapy. In 
      addition, this combination therapy has demonstrated a controllable safety 
      profile. However, further validation is urgently needed through randomized 
      controlled trials with large sample sizes.
CI  - Copyright (c) 2023 Chen, Cai, Wu, Tang, Chen, Wang, Zhuang and Guo.
FAU - Chen, Song
AU  - Chen S
AD  - Department of Minimally Invasive Interventional Therapy, State Key Laboratory of 
      Oncology in South China, Guangdong Provincial Clinical Research Center for 
      Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Cai, Hongjie
AU  - Cai H
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Wu, Zhiqiang
AU  - Wu Z
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Tang, Shuangyan
AU  - Tang S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Chen, Ludan
AU  - Chen L
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Wang, Fan
AU  - Wang F
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Zhuang, Wenquan
AU  - Zhuang W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Guo, Wenbo
AU  - Guo W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20231122
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10702964
OTO - NOTNLM
OT  - anlotinib
OT  - combination therapy
OT  - hepatitis B virus
OT  - transarterial chemoembolization
OT  - unresectable hepatocellular carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/12/11 06:45
MHDA- 2023/12/11 06:46
PMCR- 2023/01/01
CRDT- 2023/12/11 05:46
PHST- 2023/06/06 00:00 [received]
PHST- 2023/11/06 00:00 [accepted]
PHST- 2023/12/11 06:46 [medline]
PHST- 2023/12/11 06:45 [pubmed]
PHST- 2023/12/11 05:46 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1235786 [doi]
PST - epublish
SO  - Front Oncol. 2023 Nov 22;13:1235786. doi: 10.3389/fonc.2023.1235786. eCollection 
      2023.